CLLS Stock Analysis: Buy, Sell, or Hold?
CLLS - Cellectis S.A. American Depositary Shares
$3.79
-0.20 (-5.01%)
▼
HOLD
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Mar 12, 2026
Get Alerted When CLLS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CLLS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: CLLS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: CLLS is currently trading at $3.79, which is considered oversold relative to its 30-day fair value range of $4.07 to $4.70.
Technical Outlook: Technically, CLLS is in a strong uptrend. The price is currently testing key support at $3.78. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.0% recently.
Market Sentiment: CLLS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $7.00 (+84.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CLLS is in a strong uptrend. The price is currently testing key support at $3.78. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.0% recently.
Market Sentiment: CLLS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $7.00 (+84.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$4.07 -
$4.70
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
Protect Your Profits
Holding CLLS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.0%)
- BULLISH: Trading 84.7% below Wall St target ($7.00)
- CAUTION: 5-day price weakness (-14.3%) - monitor closely
Fair Price Analysis
30-Day Fair Range
$4.07 -
$4.70
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$3.78
Resistance Level
$4.50
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
-6.11
Wall Street Target
$7.00
(+84.7%)
Revenue Growth (YoY)
105.9%
Profit Margin
-42.8%
Last updated: February 01, 2026 2:10 AM ET
Data refreshes hourly during market hours. Next update: 3:10 AM
Data refreshes hourly during market hours. Next update: 3:10 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CLLS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 59 HOLD |
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$22 | 60 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$83 | 57 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$117 | 59 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$141 | 59 HOLD |
Advanced CLLS Option Strategies
Professional options setups generated by AI based on today's CLLS price and gamma walls.
